The approval of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC) has expanded the armamentarium against this disease.This paper will review the historical progress and recent clinical developments of anti-EGFR therapies in the treatment of metastatic CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.